$0.89 -$0.05 (0.0%)

04:30 PM EDT on 04/22/19

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED)

CAPS Rating: No stars

Current Price $0.89 Mkt Cap $34.43
Open $0.94 P/E Ratio 0.00
Prev. Close $0.89 Div. (Yield) $0.00 (0.0%)
Daily Range $0.87 - $0.94 Volume 74,375
52-Wk Range $0.66 - $1.27 Avg. Daily Vol. 12


This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

22 Outperform
2 Underperform

All-Star Players

3 Outperform
1 Underperform

Wall Street

0 Outperform
1 Underperform

Top NASDAQ:OMED Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Tophinater (50.73)
Submitted November 17, 2014

i don't know.

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!


Fools bullish on NASDAQ:OMED are also bullish on:

Fools bearish on NASDAQ:OMED are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about OMED.


Member Avatar DeathStock (57.76) Submitted: 4/10/2017 4:23:29 PM : Outperform Start Price: $5.51 NASDAQ:OMED Score: -118.20

Not really a fan of this company or stock but I'll take a chance with a 200M market cap in place now as it was overpriced from the IPO.


Member Avatar biotechf (94.72) Submitted: 7/17/2015 1:54:24 PM : Outperform Start Price: $21.43 NASDAQ:OMED Score: -145.28

Oncomed's two most promising cancer treatments are demcizumab and tarextumab targeting difficult to treat cancers. Positive clinical trial results should give these shares a boost. Both of these drugs have partnerships: demcizumab (Celgene) and tarextumab (GSK). At $21.50 per share or about 654M market capitalization the company may increase in value if phase trial results are positive.

OncoMed is conducting two randomized Phase 2 trials of demcizumab. The YOSEMITE trial is evaluating demcizumab and gemcitabine plus Abraxane in patients with first-line metastatic pancreatic cancers. The DENALI trial will assess the efficacy of demcizumab with carboplatin and pemetrexed in first-line non-squamous NSCLC. A Phase 1b/2 trial of demcizumab and paclitaxel in patients with platinum-resistant ovarian cancer is also ongoing.

Tarextumab (anti-Notch2/3, OMP-59R5) is a novel anti-cancer stem cell antibody that prevents signaling through both the Notch2 and Notch3 receptors. Tarextumab is currently being studied in two randomized Phase 2 clinical trials. The ALPINE trial is assessing tarextumab with Abraxane plus gemcitabine in first-line advanced pancreatic cancer patients. The PINNACLE trial is testing tarextumab in combination with etoposide and cisplatin and etoposide and carboplatin in first-line extensive stage small cell lung cancer patients.


Member Avatar sullyz0r (65.54) Submitted: 5/28/2015 2:20:24 PM : Outperform Start Price: $23.83 NASDAQ:OMED Score: -145.52

I'm actually not a huge fan of the "cancer stem cell" hypothesis, but I like this company a lot more for its notch/wnt pathway target pipeline.


Find the members with the highest scoring picks in OMED.

Score Leader


TrackJimCramer (86.92) Score: +174.33

The Score Leader is the player with the highest score across all their picks in OMED.

Member Name Member
Call Time
Score Commentary
wadea1 < 20 1/28/2016 Underperform 5Y $8.94 -90.04% +67.17% +157.21 0 Comment
tstapez22 28.16 3/8/2018 Outperform 5Y $2.87 -68.99% +15.83% -84.82 0 Comment
risktech 37.22 3/29/2018 Outperform 5Y $3.12 -71.47% +21.34% -92.82 0 Comment
DeathStock 57.76 4/10/2017 Outperform 5Y $5.51 -83.85% +34.35% -118.20 1 Comment
mistermiranga 99.81 7/7/2016 Outperform 5Y $12.69 -92.99% +51.45% -144.44 0 Comment
biotechf 94.72 7/17/2015 Outperform 1Y $21.43 -95.85% +49.43% -145.28 1 Comment
sullyz0r 65.54 5/28/2015 Outperform 5Y $23.83 -96.27% +49.26% -145.52 1 Comment
TruffelPig < 20 3/20/2015 Outperform 5Y $27.11 -96.72% +51.09% -147.81 0 Comment
Alonsohelps < 20 8/19/2015 Outperform 3M $21.81 -95.92% +52.00% -147.91 0 Comment
stainsolution < 20 3/31/2015 Outperform 5Y $25.78 -96.55% +53.25% -149.79 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for OMED.